All respiratory syncytial virus articles
-
NewsStudy supports effectiveness of RSV preventive antibody treatments for infants and provides new way to monitor viral resistance
An analysis of more than 60,000 respiratory syncytial virus (RSV) sequences from around the world found that viral variants associated with resistance to current RSV prevention tools remain rare, according to a study.
-
NewsImmunization to prevent RSV in infants reduced ICU admissions by 97 per cent
A new immunization, offered free to all infants through universal programs in two Canadian provinces, provided strong protection against respiratory syncytial virus, commonly referred to as RSV, sharply reducing hospitalizations and intensive care unit (ICU) admissions in infants.
-
NewsTissue-resident immune cells defend human lungs from viral, bacterial, and fungal infections
A study shows that human lung tissue serves as a “reservoir” for a large number of tissue-resident memory T cells.. These cells stand ready to combat a surprising range of viruses, bacteria, and even deadly fungal pathogens.
-
NewsHow did the COVID-19 pandemic shift seasonal surges of other respiratory diseases?
A new analysis explores what underlies shifts in the timing of seasonal surges of respiratory diseases, as well as shifts in surges of heart-related deaths, that occurred after the COVID-19 pandemic began.
-
NewsNew clues raise hopes for better treatment of RSV in babies
Future therapies for respiratory syncytial virus must target both the virus and its immune response to ensure babies get the best possible outcomes, finds a new study that developed a lab model of baby lungs to show why RSV makes infants so much sicker than adults.
-
NewsFrom infancy to old age, nationwide China study maps how serious lung infections change across life stages
An analysis of 695,142 hospitalized patients identifies eight life-stage pathogen profiles, three co-detection networks, and marked male predominance in bacterial and fungal infections.
-
NewsStudy: Three-in-one vaccine shows promise against ‘tripledemic’
A single-shot vaccine in development could protect against flu, COVID-19 and RSV simultaneously. In a study, researchers found that their three-in-one vaccine triggered protective immunity against all three respiratory diseases in mice, ferrets and cotton rats.
-
NewsMaternal RSV vaccine cuts infant hospitalizations by 70%
A study has found that vaccination against respiratory syncytial virus (RSV) during pregnancy reduced the risk of hospitalization in young infants by nearly 70%. It provides early real-world evidence from U.S. clinical care, showing that administering one dose of the maternal RSV vaccine (RSVpreF vaccine) reduces hospitalization related to RSV in young infants.
-
NewsMaternal RSV vaccination cuts infant hospitalization risk by over 80%, major study finds
The largest real-world study of its kind shows that maternal vaccination against respiratory syncytial virus (RSV) reduces the risk of hospitalisation in young infants by over 80% when given at least two weeks before birth.
-
NewsDiffering immune responses in infants may explain increased severity of RSV over SARS-CoV-2
Reseachers report that the two respiratory viruses trigger different immune responses. Those differences might explain why these two diseases have different clinical outcomes and require different treatment strategies.
-
NewsBeyond gene scissors: New CRISPR mechanism discovered
Two studies describe how researchers found a novel CRISPR mechanism, Cas12a2, in a family of nucleases that exclusively cleave DNA. In contrast, Cas12a2 was able to broadly cleave both RNA and DNA.
-
NewsHuman ‘mini-noses’ help understand why RSV infections are more severe in children than in adults
Why does RSV affect babies more severely? To better understand the cellular reasons behind this age-related difference, researchers compared infant and adult human nose organoids, also called mini-noses, regarding their susceptibility and response to infection.
-
NewsProtecting infants against respiratory syncytial virus this winter — ECDC issues advice
ECDC has issued rapid scientific advice for policymakers and public health authorities on ways to mitigate the impact of RSV disease among infants through immunisation and to support intensified efforts to protect them from RSV across Europe.
-
NewsNot just a common cold: studies show RSV’s severity and impact on long-term health
Often confused for a common cold, respiratory syncytial virus (RSV) can in fact be serious and should be studied more closely. Researchers found that the illness could be of comparable severity to other more well-known respiratory viral infections (RVIs) – such as influenza and COVID-19.
-
NewsAI can speed antibody design to thwart novel viruses: study
Artificial intelligence (AI) and “protein language” models can speed the design of monoclonal antibodies that prevent or reduce the severity of potentially life-threatening viral infections, according to a multi-institutional study
-
NewsRSV vaccines safe and effective, Cochrane review finds
A new Cochrane review demonstrates that vaccines for respiratory syncytial virus (RSV) are both safe and effective in protecting vulnerable groups that are most at risk of serious illness, including older adults and infants.
-
NewsEven healthy children can be severely affected by RSV
It is not only premature babies and children with underlying diseases who suffer from serious respiratory syncytial virus (RSV) infections. Even healthy, full-term babies are at significant risk of intensive care or prolonged hospitalisation – especially during the first three months of life.
-
NewsOne shot of RSV vaccine effective against hospitalization in older adults for two seasons
One shot of an RSV vaccine protects adults ages 60 or older from RSV-associated hospitalization and critical illness during two consecutive RSV seasons, according to a new study.
-
NewsNew jab protects babies from serious lung infection, study shows
Vaccination of pregnant women has been linked to a drop in newborns being admitted to hospital with a serious lung infection, research suggests.
-
NewsMonoclonal antibody nirsevimab provides strong protection against severe RSV in infants
Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial virus (RSV) infections in infants, suggests a meta-analysis.